AneuroTech is invited to attend the Jefferies London Healthcare Conference on November 15-17, 2022 at the Waldorf Hilton (Aldwych) in London. This year marks the 13th anniversary of the largest healthcare-dedicated conference in Europe. In 2021, we hosted over 650 healthcare companies, 3,000 attendees, and nearly 8,000 investor and business-to-business meetings. Our conference will again… Read more »
The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October 13 and 14, 2022 in Paris.25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of… Read more »
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder Seasoned biotech entrepreneur Dr Rudi Pauwels joins ANeuroTech as Executive Chairman Alken, Belgium – July 5, 2022: ANeuroTech, a leader in the development of innovative mental health treatments with minimal… Read more »
FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD). The emerging clinical late stage biopharmaceutical company ANEUROTECH have – as an outcome of the FDA Pre-IND Meeting on 19JAN2021 – reached out an agreement with the FDA to continue with its submitted Pivotal Phase IIIB development program on ANT01 in the higly… Read more »
*Flatt et al, Alzheimer’s Dement. 2021;7:e12197. Indicating need for effective treatment of Major Depressive Disorder with associated Subjective Cognitive Decline (MDD-SCD). Intro: AbstractIntroduction: Subjective cognitive decline (SCD) represents self-reported problems with memory, a possible early sign of dementia. Little is known about SCD among sexual and gender minority (SGM) adults who identify as lesbian, gay,… Read more »
